Mifepristone is a medicine used mainly to end an early pregnancy, often together with misoprostol. It's also used for some cases of Cushing's syndrome. Mifepristone and misoprostol are two medications commonly used together in medication abortion (also called the "abortion pill") to end an early pregnancy. They are also used for managing early pregnancy loss (miscarriage). Some "Pro-life" advocates have suggested that the expanded use of this medication in a domestic setting, i.e., at home, and not a medical facility will overwhelm the ability of the conventional domestic wastewater treatment plants that service these patients.

The Answer: Mifepristone is effectively removed in conventional wastewater treatment plants (WWTPs), primarily through sorption (binding) to solid sludge rather than biodegradation. The primary concern is not related to the potential impacts or effects at the point of discharge, but the potential concerns related to the accumulation of this chemical in the solids and biosolids from the facilities.

In many cases, wastewater sludges are land applied in rural areas as biosolids via a beneficial use permit. One area that the "Pro-Life" advocates did not really address is that many patients live in rural areas that do not have centralized domestic wastewater systems. In these areas, the patient only has a standard septic system. Septic systems are not designed to handle postpartum tissue or miscarriages. Therefore, the two primary areas of concern would be the accumulation in the biosolids and the fact that many rural patients have individual on-lot or land-based septic systems that were not designed to manage this type of bioproduct or waste. The "Pro-Life" groups should focus on the management of biosolids and how best to help patients in rural areas with septic systems.

Removal Mechanisms

• Sorption to solids — Mifepristone (a synthetic steroid) is lipophilic and binds strongly to organic matter, suspended solids, and sludge in primary and secondary treatment. This is the dominant removal pathway.


• Biodegradation — Limited. It is not readily biodegradable (<10% in standard 28-day OECD 301F tests). However, it undergoes transformation/degradation in aquatic sediment systems (OECD 308), with significant reduction over time as it partitions to sediment.


• Overall efficiency — Experts (e.g., molecular toxicologists) state that most modern WWTPs are very effective at removing it. It is typically not detected (or greatly reduced) in treated effluent.

In one monitored case, mifepristone was detected in raw (untreated) wastewater at one plant but was removed after treatment.

Real-World Context

• Influent concentrations — Extremely low (usually ng/L range or below detection) due to low usage volume compared to other drugs.


• Effluent — Trace amounts that remain are further reduced by dilution in receiving waters. Advanced treatments (e.g., ozonation, activated carbon) can achieve even higher removal if needed.


• Sludge — The bound fraction ends up in biosolids, which may be land-applied or incinerated, further limiting environmental release.

Regulatory View (FDA)

FDA environmental assessments (including updates) use conservative assumptions (e.g., 0% removal in some calculations) but still conclude no significant environmental impact. Actual treatment provides an additional safety margin.

Summary

Standard wastewater treatment (activated sludge + solids separation) removes the vast majority of mifepristone via binding to sludge. It is not a persistent or difficult-to-remove compound in practice, and environmental concentrations remain negligible. Claims of widespread passage through treatment plants are not supported by available data. For the most technical details, see FDA dockets or Swedish environmental classification documents on mifepristone.

Special Case: Septic Systems

This article focuses on conventional municipal wastewater treatment. Septic systems typically achieve lower and more variable removal of pharmaceuticals than modern treatment plants. While absolute environmental concentrations of mifepristone (or its metabolites) remain extremely low due to limited usage and rapid degradation, individuals on septic systems should be aware that residuals may reach groundwater or surface water with less attenuation.

Septic systems are primarily designed for the treatment of domestic wastewater generated from household activities, such as bathing, cooking, and toilet use. They consist of a septic tank and a drainfield, which work together to treat and disperse wastewater safely into the environment. Septic systems are not designed to handle postpartum tissue or miscarriages.

We would recommend that this chemical not be used for patients that rely on septic systems and that the patient should be treated at a medical facility with the appropriate systems. In summary, septic systems should not be used for disposing of postpartum tissue or miscarriages, and appropriate medical disposal methods should be followed instead.

Key Sources

1. FDA Environmental Assessment for Mifepristone (2000 NDA)
   accessdata.fda.gov/drugsatfda_docs/nda/2000/20687_Mifepristone_EA.pdf
   Official FDA document assessing environmental entry via excretion and concluding no significant impact.
2. FDA Docket Response – Environmental Considerations (2025)
   downloads.regulations.gov/FDA-2023-P-1528-0005/attachment_1.pdf
   Discusses wastewater treatment plant removal efficiency, metabolism, and conservative calculations showing negligible risk.
3. Janusinfo (Sweden) – Mifepristone Environmental Classification
   janusinfo.se — Mifepristone
   Detailed data on persistence, DT50 values in water/sediment systems, low bioaccumulation, and low risk downstream of WWTPs.
4. PolitiFact Article on Mifepristone in Wastewater
   politifact.com — Mifepristone in Wastewater
   References studies showing mifepristone detected in raw wastewater at one plant but removed after treatment.
5. Occurrence and Removal of Progestagens in Municipal WWTPs (ScienceDirect, 2019)
   sciencedirect.com — Progestagens in WWTPs
   Study including mifepristone among progestagens; shows high removal efficiency (>90% for several, including efficient removal for mifepristone in many plants).
6. FDA Mifepristone Linepharma Environmental Risk Classification (Swedish data with PEC calculations)
   downloads.regulations.gov/FDA-2023-P-1528-0007/content.pdf
   Includes removal assumptions, PEC calculations, and WWTP fate details.

These sources consistently indicate that conventional wastewater treatment (especially sorption to sludge) removes most mifepristone, with concentrations downstream typically very low (often <0.1–few ng/L). The primary issue would be related to biosolids treatment and management and that this approach to ending pregnancy may not be advisable for patients that use individual or community septic systems.